SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel...
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its...
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a...
Rosnilimab was safe and well tolerated with similar adverse event rates vs . placebo Observed expected pharmacology, including ~90% depletion of pathogenic T cells, however lack of adequate efficacy...
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel...
Announced intent to separate biopharma operations from substantial royalty assets by YE 2026 Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on...
New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced therapy,...
In a report released today, Joon Lee from Truist Financial maintained a Hold rating on AnaptysBio. The company’s shares closed yesterday at $31.85.Elevate Your Investing Strategy: Take advantage of TipRanks...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Microbot Medical (MBOT – Research Report), Argenx Se (ARGX – Research Report) and AnaptysBio (ANAB –...
In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on AnaptysBio, with a price target of $72.00. The company’s shares closed yesterday at $32.46.Elevate Your Investing...